Astrazeneca’s $85m Quell collaboration comes after Regeneron’s tie-up with Sonoma and Lilly’s deal with Trex.
Hopes are high that a buyer will emerge, but the fast-moving downfall of a big name in biopharma banking is not over yet.
Evaluate Vantage's coverage of the Ash 2022 congress.
Meanwhile, there was bad blood between cell therapy players and their investors.
Sangamo emulates Editas, while Crispr/Vertex and Bluebird add weight to their ambitions.
The approval is good for CSL, and better for Uniqure.
Vyvgart gets a prestigious press slot for its next potential use, while Sangamo’s haemophilia A gene therapy mimics Biomarin’s valrox again.